Italy’s Newron files Parkinson’s drug with FDA

New Drug Approvals

SAFINAMIDE

cas  202825-46-5 (mesylate)

N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide

Newron Pharmaceuticals and fellow Italy-headquartered partner Zambon have filed their investigational Parkinson’s disease treatment safinamide with regulators in the USA.

The submission to the US Food and Drug Administration is for safinamide as add-on therapy in early and mid-to late stage PD patients. Newron said the filing was based on “completion of activities agreed upon during meetings” with the FDA, noting that a marketing authorisation application was submitted to the European Medicines Agency in December.

Read more at: http://www.pharmatimes.com/Article/14-05-30/Italy_s_Newron_files_Parkinson_s_drug_with_FDA.aspx#ixzz33LlGLEt7

133865-89-1, Fce 26743, AC1L2ZLK, CHEMBL396778, MolPort-005-942-375,
Fce-26743, (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide
Molecular Formula: C17H19FN2O2   Molecular Weight: 302.343363

Safinamide (EMD 1195686) is a candidate drug against Parkinson’s disease with multiple methods of action.[1] In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011.[2] The compound was originally discovered at Farmitalia-Carlo…

View original post 494 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s